Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis

BackgroundThe optimal (neo)adjuvant regimen for human epidermal growth factor receptor-2 (HER2)-positive breast cancer regarding survival outcomes remains unclear.MethodsWe searched Web of Science, PubMed, and the Cochrane Central Register of Controlled Trials systematically to find out randomized c...

Full description

Bibliographic Details
Main Authors: Yu-Wen Cai, Zhi-Ming Shao, Ke-Da Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
breast cancer
(neo)adjuvant
HER2-positive
disease-free survival
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.919369/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.919369/full

Similar Items